These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 39136571)

  • 1. Fluctuating obliterative bronchiolitis in RET-mutant medullary thyroid cancer patient treated with selpercatinib.
    Gambale C; Prete A; Romei C; Celi A; Elisei R; Matrone A
    Eur Thyroid J; 2024 Oct; 13(5):. PubMed ID: 39136571
    [TBL] [Abstract][Full Text] [Related]  

  • 2. LIBRETTO-531: a phase III study of selpercatinib in multikinase inhibitor-naïve
    Wirth LJ; Brose MS; Elisei R; Capdevila J; Hoff AO; Hu MI; Tahara M; Robinson B; Gao M; Xia M; Maeda P; Sherman E
    Future Oncol; 2022 Sep; 18(28):3143-3150. PubMed ID: 35969032
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Primary resistance to selpercatinib in a patient with advanced medullary thyroid cancer.
    Pitoia F; Trimboli P; Abelleira E
    Endocrine; 2024 Oct; 86(1):109-113. PubMed ID: 38801596
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Durability of Response With Selpercatinib in Patients With
    Wirth LJ; Brose MS; Subbiah V; Worden F; Solomon B; Robinson B; Hadoux J; Tomasini P; Weiler D; Deschler-Baier B; Tan DSW; Maeda P; Lin Y; Singh R; Bayt T; Drilon A; Cassier PA
    J Clin Oncol; 2024 Sep; 42(27):3187-3195. PubMed ID: 39094065
    [No Abstract]   [Full Text] [Related]  

  • 5. Efficacy of Selpercatinib in
    Wirth LJ; Sherman E; Robinson B; Solomon B; Kang H; Lorch J; Worden F; Brose M; Patel J; Leboulleux S; Godbert Y; Barlesi F; Morris JC; Owonikoko TK; Tan DSW; Gautschi O; Weiss J; de la Fouchardière C; Burkard ME; Laskin J; Taylor MH; Kroiss M; Medioni J; Goldman JW; Bauer TM; Levy B; Zhu VW; Lakhani N; Moreno V; Ebata K; Nguyen M; Heirich D; Zhu EY; Huang X; Yang L; Kherani J; Rothenberg SM; Drilon A; Subbiah V; Shah MH; Cabanillas ME
    N Engl J Med; 2020 Aug; 383(9):825-835. PubMed ID: 32846061
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neoadjuvant selpercatinib for advanced medullary thyroid cancer.
    Jozaghi Y; Zafereo M; Williams MD; Gule-Monroe MK; Wang J; Grubbs EG; Vaporciyan A; Hu MI; Busaidy N; Dadu R; Waguespack SG; Subbiah V; Cabanillas M
    Head Neck; 2021 Jan; 43(1):E7-E12. PubMed ID: 33169506
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study.
    Subbiah V; Hu MI; Wirth LJ; Schuler M; Mansfield AS; Curigliano G; Brose MS; Zhu VW; Leboulleux S; Bowles DW; Baik CS; Adkins D; Keam B; Matos I; Garralda E; Gainor JF; Lopes G; Lin CC; Godbert Y; Sarker D; Miller SG; Clifford C; Zhang H; Turner CD; Taylor MH
    Lancet Diabetes Endocrinol; 2021 Aug; 9(8):491-501. PubMed ID: 34118198
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular genetics, therapeutics and RET inhibitor resistance for medullary thyroid carcinoma and future perspectives.
    Zhang Y; Zheng WH; Zhou SH; Gu JL; Yu Q; Zhu YZ; Yan YJ; Zhu Z; Shang JB
    Cell Commun Signal; 2024 Sep; 22(1):460. PubMed ID: 39342195
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Emergence of Resistant Clones in Medullary Thyroid Cancer May Not Be Rescued by Subsequent Salvage Highly Selective Rearranged During Transfection-Inhibitor Therapy.
    Bruce JY; Bible KC; Chintakuntlawar AV
    Thyroid; 2021 Feb; 31(2):332-333. PubMed ID: 32664802
    [No Abstract]   [Full Text] [Related]  

  • 10. Somatic RET Indels in Sporadic Medullary Thyroid Cancer: Prevalence and Response to Selpercatinib.
    Elisei R; Ciampi R; Matrone A; Prete A; Gambale C; Ramone T; Simeakis G; Materazzi G; Torregrossa L; Ugolini C; Romei C
    J Clin Endocrinol Metab; 2022 Jul; 107(8):2195-2202. PubMed ID: 35616103
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Precision Targeted Therapy with BLU-667 for
    Subbiah V; Gainor JF; Rahal R; Brubaker JD; Kim JL; Maynard M; Hu W; Cao Q; Sheets MP; Wilson D; Wilson KJ; DiPietro L; Fleming P; Palmer M; Hu MI; Wirth L; Brose MS; Ou SI; Taylor M; Garralda E; Miller S; Wolf B; Lengauer C; Guzi T; Evans EK
    Cancer Discov; 2018 Jul; 8(7):836-849. PubMed ID: 29657135
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of Tyrosine Kinase Inhibitors for Treatment of Medullary Thyroid Carcinoma.
    Dadu R; Hu MN; Grubbs EG; Gagel RF
    Recent Results Cancer Res; 2015; 204():227-49. PubMed ID: 26494392
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patient-Reported Outcomes with Selpercatinib Treatment Among Patients with RET-Mutant Medullary Thyroid Cancer in the Phase I/II LIBRETTO-001 Trial.
    Wirth LJ; Robinson B; Boni V; Tan DSW; McCoach C; Massarelli E; Hess LM; Jen MH; Kherani J; Olek E; Subbiah V
    Oncologist; 2022 Feb; 27(1):13-21. PubMed ID: 34516023
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Management of Advanced Medullary Thyroid Carcinoma: Current Systemic Therapy Options.
    Jara MA
    Crit Rev Oncog; 2024; 29(3):83-90. PubMed ID: 38683155
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Initial Experiences of Selective RET Inhibitor Selpercatinib in Adults with Metastatic Differentiated Thyroid Carcinoma and Medullary Thyroid Carcinoma: Real-World Case Series in Korea.
    Baek HS; Ha J; Ha S; Bae JS; Jung CK; Lim DJ
    Curr Oncol; 2023 Mar; 30(3):3020-3031. PubMed ID: 36975442
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase 3 Trial of Selpercatinib in Advanced
    Hadoux J; Elisei R; Brose MS; Hoff AO; Robinson BG; Gao M; Jarzab B; Isaev P; Kopeckova K; Wadsley J; Führer D; Keam B; Bardet S; Sherman EJ; Tahara M; Hu MI; Singh R; Lin Y; Soldatenkova V; Wright J; Lin B; Maeda P; Capdevila J; Wirth LJ;
    N Engl J Med; 2023 Nov; 389(20):1851-1861. PubMed ID: 37870969
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cabozantinib for the treatment of progressive metastatic medullary thyroid cancer.
    Krajewska J; Olczyk T; Jarzab B
    Expert Rev Clin Pharmacol; 2016; 9(1):69-79. PubMed ID: 26536165
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selpercatinib.
    Am J Health Syst Pharm; 2020 Oct; 77(22):1818-1821. PubMed ID: 32930710
    [No Abstract]   [Full Text] [Related]  

  • 19. Selective RET kinase inhibition for patients with RET-altered cancers.
    Subbiah V; Velcheti V; Tuch BB; Ebata K; Busaidy NL; Cabanillas ME; Wirth LJ; Stock S; Smith S; Lauriault V; Corsi-Travali S; Henry D; Burkard M; Hamor R; Bouhana K; Winski S; Wallace RD; Hartley D; Rhodes S; Reddy M; Brandhuber BJ; Andrews S; Rothenberg SM; Drilon A
    Ann Oncol; 2018 Aug; 29(8):1869-1876. PubMed ID: 29912274
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selpercatinib Treatment of RET-Mutated Thyroid Cancers Is Associated With Gastrointestinal Adverse Effects.
    Tsang V; Gill A; Gild M; Lurie B; Blumer L; Siddall R; Clifton-Bligh R; Robinson B
    J Clin Endocrinol Metab; 2022 Aug; 107(9):e3824-e3829. PubMed ID: 35647935
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.